Company news

Mesoblast Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Use of Ryoncil Highlighted in Key Opinion Leader Webinar

November 4, 2026

Final Director's Interest Notice

November 1, 2026

Mesoblast Board Changes

November 1, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 28, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 28, 2026

Becoming a substantial holder

October 27, 2026

Ceasing to be a substantial holder

October 26, 2026

Becoming a substantial holder

October 22, 2026

MSB Reports Increased Revenue and Improved Operating Spend

October 15, 2026

Notification of cessation of securities - MSB

October 14, 2026

Notification regarding unquoted securities - MSB

October 14, 2026

Application for quotation of securities - MSB

October 14, 2026

Annual Report to Shareholders

October 12, 2026

Notice of Annual General Meeting and Proxy Form

October 12, 2026

Appendix 4G and Corporate Governance Statement

October 12, 2026

Ceasing to be a substantial holder

October 1, 2026

Becoming a substantial holder

September 30, 2026

FDA Approves New Potency Assay for Commercial Ryoncil

September 23, 2026

Ceasing to be a substantial holder

September 23, 2026

Annual Report for Fiscal Year Ending June 30, 2026 (Form 20-F)

August 27, 2026

Mesoblast Reports Substantial Revenue Growth to US$120M

August 26, 2026

MSB Annual Financial Results and Operational Update

August 26, 2026

Annual Financial Results Presentation

August 26, 2026

Preliminary Final Report including Appendix 4E

August 26, 2026

Appendix 3Y - Philip Krause

August 24, 2026

Notification regarding unquoted securities - MSB

August 24, 2026

Mesoblast 2026 Full Year Financial Results Webcast

August 24, 2026

Major Milestone Treatment Completed in P3 Trial for CLBP

August 16, 2026

Becoming a substantial holder

August 13, 2026

Ceasing to be a substantial holder

August 7, 2026

Becoming a substantial holder

August 5, 2026

Ceasing to be a substantial holder

August 3, 2026

Becoming a substantial holder

July 31, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

July 29, 2026

Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch

July 28, 2026

Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain

July 13, 2026

Pivotal Phase 3 Trial in CLBP Achieves 300 Treated Patients

July 13, 2026

Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026

July 9, 2026

Ryoncil Q4 Net Revenue of US$36M and US$115M for Full Year

July 9, 2026

Mesoblast Draws US$50M from Five-Year Non-Dilutive Facility

June 24, 2026

Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million

April 28, 2026

Patient Recruitment Target Achieved in CLBP Pivotal Trial

April 29, 2026

Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain

April 28, 2026

Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products

April 14, 2026

Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION

April 10, 2026

Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation

April 8, 2026

Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy

April 6, 2026

Ryoncil Net Revenue for the Quarter Increases to US$30.3M

April 7, 2026

Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter

April 5, 2026

Mesoblast to Host R&D Day on April 8, 2026

March 17, 2026

Older news releases →

Calls

The 5 newest of 10 calls. Every call is listed under its year.

Decks

The 5 newest of 105 decks. Every deck is listed under its year.